Lungs News and Research

RSS

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has published results from its Phase II GEMINI study in the Proceedings of the National Academy of Sciences (PNAS). These data, previously presented at the International Symposium on Respiratory Viral Infections in Singapore in 2008, showed human proof of concept with an RNAi therapeutic in a randomized, double blind, placebo-controlled study.

27 Apr 2010

Pharmacological suppression of nonsense mutations effective in treating genetic defects

Genetic mutation can disrupt the way human cells make proteins, which in turn leads to inherited disease. David Bedwell, a professor in the University of Alabama at Birmingham (UAB) Department of Microbiology, says scientists are closer than ever to producing drugs that fix this disrupted-protein pathway and drastically improving treatment of genetic disease.

27 Apr 2010

Medication-free home ventilation system designed to remove allergens

According to a recent report by USA Today, due to 2010's unusually cold winter temperatures, allergy sufferers are now poised to experience the worst pollen season in years, with pollen counts skyrocketing and sufferers hiding indoors to avoid exposure. Yet as allergens creep indoors, sufferers continue to cough, sneeze and seek relief. With the introduction of EZ Breathe, a new innovative home ventilation system designed to remove allergens and reduce indoor concentrations of pollen, allergy sufferers now have a medication-free solution.

27 Apr 2010

Scientists now closer to produce drugs to fix disease-causing mutations, spare healthy genes

Inherited diseases such as cystic fibrosis can be caused by genetic "nonsense mutations" that disrupt the way human cells make proteins. David Bedwell, Ph.D., a professor in the University of Alabama at Birmingham Department of Microbiology, says scientists are now closer to producing drugs that will fix this disruption and drastically improve treatment of genetic disease.

27 Apr 2010

Melanin-covered nanoparticles may protect bone marrow from harmful radiation therapy effects: Research

Tiny, melanin-covered nanoparticles may protect bone marrow from the harmful effects of radiation therapy, according to scientists at Albert Einstein College of Medicine of Yeshiva University who successfully tested the strategy in mouse models.

27 Apr 2010

New report on women's largest cancer challenge: lung cancer

Out of the Shadows: Women and Lung Cancer, a groundbreaking report released today by the Mary Horrigan Connors Center for Women's Health at Brigham and Women's Hospital, a teaching affiliate of Harvard Medical School, is a call to action on women's largest cancer challenge: lung cancer.

27 Apr 2010

ERCC1 Analysis guides patient treatment decisions

Moffitt Cancer Center announces steadily growing interest in the ERCC1 Analysis, the first test developed for selecting chemotherapy for Non Small Lung Cancer patients. Each year, more than 200,000 Americans are diagnosed with lung cancer.

26 Apr 2010

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

OSI Pharmaceuticals, Inc. announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva (erlotinib) as an adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer who have undergone surgery and have EGFR-positive tumors.

26 Apr 2010

Duke University Medical Center installs Veran Medical Technologies' SPiN Drive system

Veran Medical Technologies announced today that it has recently completed its first installation and performed several procedures at Duke University Medical Center with its FDA-cleared SPiN Drive product. The product enables clinicians to navigate deep into the peripheral regions of the lungs to access, biopsy and treat potentially cancerous Solitary Pulmonary Nodules.

26 Apr 2010

Study confirms utility of Oxford Immunotec's T-SPOT.TB assay in identifying latent TB infection

The authors of a recent peer-reviewed study published in the International Journal of Tuberculosis and Lung Disease confirmed the high specificity of the T-SPOT.TB assay.

26 Apr 2010

Pevion Biotech to present positive results of PEV4 RSV vaccine candidate at Vaccine Innovation Meeting

Pevion Biotech, the Swiss vaccine company, today announced that it has successfully completed the preclinical safety and efficacy studies of its RSV vaccine candidate PEV4. The vaccine candidate is a modern subunit vaccine candidate against respiratory syncytial virus (RSV), which is based on a recombinant RSV-F protein formulated with Pevion Biotech's proprietary and market-validated virosome technology platform.

26 Apr 2010

DeCODE scientists discover common SNPs that increase number of CPD and risk of lung cancer

Cigarette smoking is a major cause of illness and death worldwide. But it is a complex behavior, and how much people smoke, how hard they find it to quit, and the impact of long-term smoking on health varies greatly among individuals. A substantial portion of this variability is genetic. Two years ago, deCODE discovered the first common, single-letter variation in the sequence of the human genome, on chromosome 15q25, associated with nicotine addiction and risk of lung cancer.

26 Apr 2010

Report shares what women need to know and what women can do

Lung Cancer Alliance hailed today's release of "Out of the Shadows: Women and Lung Cancer," a groundbreaking report issued by the Mary Horrigan Connors Center at Brigham and Women's Hospital, a teaching affiliate of Harvard Medical School.

26 Apr 2010

Cedars-Sinai Heart Institute presents new findings on heart transplantation rejection factors

Physician scientists at the Cedars-Sinai Heart Institute are presenting new findings on heart transplantation rejection factors such as race and gender, the effects of pre-transplant smoking and whether homeless organ donors put recipients at higher risk for complications. The presentations will take place April 21 - 24 in Chicago during the 30th Annual Scientific Meeting of the International Society of Heart and Lung Transplantation.

26 Apr 2010

Three genetic regions associated with cigarette smoking

A team of scientists has used data from genome-wide association studies to identify genetic variants associated with key smoking behaviors that have a significant impact on health.

26 Apr 2010

Genes that predispose to smoking behavior and lung cancer identified: More reason to quit say researchers

According to new research there are certain genes in a smoker that make it difficult for them to cut down or quit the bad habit. This report from three studies published in the journal Nature Genetics mentions at least three different genetic mutations on chromosome 15 or changes that can increase the number of cigarettes smoked per day by an individual.

25 Apr 2010

Targeted therapy based on molecular signatures for treating lung cancer

The first lung cancer clinical trial to guide targeted therapies to patients based on molecular signatures in tumor biopsies is a step toward personalized care and more effective, efficient clinical trials for new drugs, study leaders reported today during the American Association for Cancer Research 101st Annual Meeting 2010.

24 Apr 2010

Highlights from AACE 19th Annual Meeting and Clinical Congress

today's highlights from the AACE Annual Meeting & Clinical Congress in Boston

24 Apr 2010

Novel clinical research approaches for rapidly identifying and preventing congenital cardiovascular defects

Structural and functional congenital cardiovascular abnormalities present at birth are the leading source of all congenital defects encountered in live births. Nearly half a million children in the United States have structural heart problems ranging in severity from relatively simple issues, such as small holes between chambers of the heart, to very severe malformations, including complete absence of one or more chambers or valves.

24 Apr 2010

Study finds AFREZZA comparable to standard of care insulin therapy

Pulmonary function test results (PFTs) in patients treated with AFREZZATM (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, ultra rapid acting insulin, at follow-up measurements were similar to PFT results observed in patients receiving standard antidiabetic therapy, according to data presented today at the American Association of Clinical Endocrinologists 19th Annual Meeting (Poster #267).

24 Apr 2010

Lungs News and Research

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

Pharmacological suppression of nonsense mutations effective in treating genetic defects

Medication-free home ventilation system designed to remove allergens

Scientists now closer to produce drugs to fix disease-causing mutations, spare healthy genes

Melanin-covered nanoparticles may protect bone marrow from harmful radiation therapy effects: Research

New report on women's largest cancer challenge: lung cancer

ERCC1 Analysis guides patient treatment decisions

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

Duke University Medical Center installs Veran Medical Technologies' SPiN Drive system

Study confirms utility of Oxford Immunotec's T-SPOT.TB assay in identifying latent TB infection

Pevion Biotech to present positive results of PEV4 RSV vaccine candidate at Vaccine Innovation Meeting

DeCODE scientists discover common SNPs that increase number of CPD and risk of lung cancer

Report shares what women need to know and what women can do

Cedars-Sinai Heart Institute presents new findings on heart transplantation rejection factors

Three genetic regions associated with cigarette smoking

Genes that predispose to smoking behavior and lung cancer identified: More reason to quit say researchers

Targeted therapy based on molecular signatures for treating lung cancer

Highlights from AACE 19th Annual Meeting and Clinical Congress

Novel clinical research approaches for rapidly identifying and preventing congenital cardiovascular defects

Study finds AFREZZA comparable to standard of care insulin therapy

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News